article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

article thumbnail

Missouri Republican,Michael Davis, proposes adding access to LSD, MDMA, peyote, and psilocybin as treatment options

Cannabis Law Report

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Missouri has had its own version of right-to-try since 2014.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. No drug is without risks, so clinical trials have included careful investigation of possible adverse effects.

Therapy 52
article thumbnail

Press Release: MAPS Places Fully Validated, Multi-Kilogram Synthesis of MDMA in the Public Domain?

Cannabis Law Report

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. April 5, 2022.

article thumbnail

United States Minor Cannabinoids (CBG, CBC, CBN, THCV, CBGA) Markets Report 2021-2028 – ResearchAndMarkets.com

Cannabis Law Report

In addition, rising strategic initiatives by key players in the form of collaborations, clinical trials, and production are further contributing to increasing awareness and adoption of THCV products. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

article thumbnail

Exclusive Worldwide License Agreement with Canopy Growth Corporation for Key Pharmaceutical Assets

Cannabis Law Report

Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. The principal objective of Programme 3 is to identify a drug candidate(s) for neuropathic pain conditions.

article thumbnail

Global Legal Cannabis Markets Analysis 2021-2028 by Sources (Marijuana, Hemp), End-use (Recreational, Medical), Derivatives (CBD, THC) – ResearchAndMarkets.com

Cannabis Law Report

Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. Global Legal Cannabis Industry: Number of Clinical Trials, By Region. Market Segmentation.